Testing for qualitative interactions between treatment effects and patient subsets.

By M. Gail, Richard M. Simon. 1985

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Using Decision Lists to Construct Interpretable and Parsimonious Treatment Regimes (2015, methodology): “Breast Cancer Data Gail and Simon (1985) compared the treatment effects of chemotherapy alone and chemotherapy with tamoxifen using data collected from the NSABP trial.”
Variable Selection for Qualitative Interactions (2011, background): “There is an abundance of literature discussing qualitative interactions (e.g. [12] [13] [9] [14] [15] [11] [16]).”
A Robust Method for Estimating Optimal Treatment Regimes (2012, methodology): “Gail and Simon (1985) applied their testing procedure for qualitative interaction to these data to conclude that there is evidence supporting the regime proposed by Fisher et al. (1983) under which subjects with age < 50 years and PR < 10 fmol receive PF, with all others receiving PFT.”
A re-evaluation of random-effects meta-analysis (2009, methodology): “…been developed (Gail and Simon, 1985; Piantadosi and Gail, 1993; Pan and Wolfe, 1997), addressing a null hypothesis: H0 :{θi < 0 ∀i} or {θi > 0 ∀i}: Gail and Simon (1985) described the use of a test statistic QÅ =min{∑ θ̂2i σ̂−2i I+i , ∑ θ̂2i σ̂−2i I−i }, .9/ where I+i =1 if θ̂i >0 and I+i =0…”
Precision Medicine. (2019, background): “…prescriptive biomarkers has been studied as a subtopic within precision medicine with early approaches seeking to identify ‘qualitative interactions’ (Gail and Simon 1985; Gunter et al 2011) and more recent approaches focused on identification of variables that are informative for identification…”
Some methods for heterogeneous treatment effect estimation in high dimensions (2017, methodology): “Early work on heterogeneous treatment eﬀect estimation (Gail and Simon, 1985) was based on comparing pre-deﬁned subpopulations of patients in randomized experiments.”